Glucagon-like peptide-1 synthetic analogs: New therapeutic agents for use in the treatment of diabetes mellitus

被引：107

作者：

Holz, GG ^{[1
]}

Chepurny, OG ^{[1
]}

机构：

[1] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA

来源：

CURRENT MEDICINAL CHEMISTRY | 2003年 / 10卷 / 22期

关键词：

GLP-1; diabetes mellitus; insulin secretion;

D O I：

10.2174/0929867033456648

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Glucagon-like peptide-1-(7-36)-amide (GLP-1) is a potent blood glucose-lowering hormone now under investigation for use as a therapeutic agent in the treatment of type 2 (adult onset) diabetes mellitus. GLP-1 binds with high affinity to G protein-coupled receptors (GPCRs) located on pancreatic beta-cells, and it exerts insulinotropic actions that include the stimulation of insulin gene transcription, insulin biosynthesis, and insulin secretion. The beneficial therapeutic action of GLP-1 also includes its ability to act as a growth factor, stimulating formation of new pancreatic islets (neogenesis) while slowing beta-cell death (apoptosis). GLP-1 belongs to a large family of structurally-related hormones and neuropeptides that include glucagon, secretin, GIP, PACAP, and VIP. Biosynthesis of GLP-1 occurs in the enteroendocrine L-cells of the distal intestine, and the release of GLP-1 into the systemic circulation accompanies ingestion of a meal. Although GLP-1 is inactivated rapidly by dipeptidyl peptidase IV (DDP-IV), synthetic analogs of GLP-1 exist, and efforts have been directed at engineering these peptides so that they are resistant to enzymatic hydrolysis. Additional modifications of GLP-1 incorporate fatty acylation and drug affinity complex (DAC) technology to improve serum albumin binding, thereby slowing renal clearance of the peptides. NN2211, LY315902, LY307161, and CJC-1131 are GLP-1 synthetic analogs that reproduce many of the biological actions of GLP-1, but with a prolonged duration of action. AC2993 (Exendin-4) is a naturally occurring peptide isolated from the lizard Heloderma, and it acts as a high affinity agonist at the GLP-1 receptor. This review summarizes structural features and signal transduction properties of GLP-1 and its cognate beta-cell GPCR. The usefulness of synthetic GLP-1 analogs as blood glucose-lowering agents is discussed, and the applicability of GLP-1 as a therapeutic agent for treatment of type 2 diabetes is highlighted.

引用

页码：2471 / 2483

页数：13

共 172 条

[11] Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1 [J].

Bulotta, A. ;

Hui, H. ;

Anastasi, E. ;

Bertolotto, C. ;

Boros, L. G. ;

Di Mario, U. ;

Perfetti, R. .

JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (03) :347-360

[12] Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1 [J].

Burcelin, R ;

Dolci, W ;

Thorens, B .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (02) :252-258

[13] Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].

Burcelin, R ;

Da Costa, A ;

Drucker, D ;

Thorens, B .

DIABETES, 2001, 50 (08) :1720-1728

[14] Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells [J].

Buteau, J ;

Roduit, R ;

Susini, S ;

Prentki, M .

DIABETOLOGIA, 1999, 42 (07) :856-864

[15] Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor [J].

Buteau, J ;

Foisy, S ;

Joly, E ;

Prentki, M .

DIABETES, 2003, 52 (01) :124-132

[16] Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation [J].

Buteau, J ;

Foisy, S ;

Rhodes, CJ ;

Carpenter, L ;

Biden, TJ ;

Prentki, M .

DIABETES, 2001, 50 (10) :2237-2243

[17] Glucagon-like peptide 1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance [J].

Byrne, MM ;

Gliem, K ;

Wank, U ;

Arnold, R ;

Katschinski, M ;

Polonsky, KS ;

Göke, B .

DIABETES, 1998, 47 (08) :1259-1265

[18] Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220 [J].

Chepurny, OG ;

Hussain, MA ;

Holz, GG .

ENDOCRINOLOGY, 2002, 143 (06) :2303-2313

[19] Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity:: a strategy for production of pancreatic β-cell lines for use in transplantation [J].

Chepurny, OG ;

Holz, GG .

CELL AND TISSUE RESEARCH, 2002, 307 (02) :191-201

[20] A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics [J].

Chou, JZ ;

Place, GD ;

Waters, DG ;

Kirkwood, JA ;

Bowsher, RR .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (07) :768-773

← 1 2 3 4 5 6 7 8 9 10 →